MaxCyte to Present Scalable Clinical and Commercial Manufacturing Technology for Cell-based and Viral-based Vaccines
GAITHERSBURG, Md., July 16 /PRNewswire/ -- MaxCyte, Inc., a
clinical-stage therapeutics company and pioneer in clinical scale,
non-viral cell loading systems, announces that Madhusudan V.
Peshwa, Ph.D., Vice President Research and Development at MaxCyte,
will present on Thursday, July 17, 2008 at 4:40PM EDT at IBC's Next
Generation Vaccines Conference at Gaylord National Resort &
Convention Center in National Harbor, MD. Dr. Peshwa's presentation
is entitled, "Scaleable Clinical and Commercial Manufacturing
Technology for Next Generation Vaccines" and will discuss how
MaxCyte's proprietary technology, which is currently being employed
in multiple clinical trials, solves the key issues of: scalability,
reproducibility, and commercial feasibility, while having a well
accepted regulatory path as well as the ability to improve upon
product titer and functional activity. Dr. Peshwa will discuss
MaxCyte's validated, regulatory-compliant technology in the context
of a manufacturing platform enabling rapid development of robust,
scalable cGMP production methods for vaccines, VLPs and viral
vectors using various flexible, single-use disposable
configurations.
About MaxCyte
MaxCyte is a clinical-stage cell therapeutics company with a
rapidly growing pipeline of product development partnerships in
cell-based therapies. The Company's proprietary, non-viral, ex vivo
cell loading technology provides safety, scalability and
reproducibility capabilities which are fundamental to
commercializing successful cell-based therapies. MaxCyte has
demonstrated the value of its versatile technology in partnered
therapeutic programs in oncology, pulmonary, metabolic and
infectious diseases as well as in development collaborations with
leading researchers. Current clinical programs with
MaxCyte-engineered cells include: a Phase IIa clinical study for
treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa
study using engineered stem cells for the treatment of primary
Pulmonary Arterial Hypertension (PAH). MaxCyte has recently
partnered with Medinet (JP) to commercialize a cell based therapy
to be launched in 2008. In addition, there are advanced preclinical
programs in oncology and regenerative medicine. More than 16
commercial and academic partners are currently using the MaxCyte
technology. The MaxCyte system has an FDA Master File in place at
the Center for Biologics Evaluation and Research (CBER).
For more information, visit http://www.maxcyte.com/.
Source: MaxCyte, Inc.
CONTACT: Anthony Recupero, Ph.D., Vice President Business
Development
MaxCyte, Inc., +1-301-944-1700
Web Site: http://www.maxcyte.com/
Posted: July 2008
